Nautilus Biotechnology (NAUT) Cash & Equivalents (2020 - 2026)

Nautilus Biotechnology has reported Cash & Equivalents for 7 years, with the latest figure at $13.2 million in Q2 2026.

• Quarterly Cash & Equivalents fell 61.79% year-over-year to $13.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $13.2 million (down 61.79% YoY) and the FY2025 annual result came in at $12.4 million, down 55.19% from the prior year.
• Cash & Equivalents eased to $13.2 million in Q2 2026 per NAUT's latest filing, from $14.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $210.4 million in Q2 2022 and troughed at $4.4 million in Q3 2024.
• A 5-year average of $65.1 million and a median of $30.4 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents soared 27556.78% in 2022, then sank 94.05% in 2024.
• Over 5 years, Cash & Equivalents stood at $114.5 million in 2022, then plunged by 83.06% to $19.4 million in 2023, then jumped by 42.53% to $27.6 million in 2024, then tumbled by 55.19% to $12.4 million in 2025, then increased by 6.28% to $13.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $13.2 million, $14.6 million, and $12.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.